Cell cycle regulation therapy combined with cytokine blockade enhances antiarthritic effects without increasing immune suppression
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cell cycle regulation therapy combined with cytokine blockade enhances antiarthritic effects without increasing immune suppression
Authors
Keywords
-
Journal
ANNALS OF THE RHEUMATIC DISEASES
Volume 75, Issue 1, Pages 253-259
Publisher
BMJ
Online
2014-08-28
DOI
10.1136/annrheumdis-2014-205566
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Abstract S1-6: Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (BC)
- (2014) RS Finn et al. CANCER RESEARCH
- Successful Treatment of Animal Models of Rheumatoid Arthritis with Small-Molecule Cyclin-Dependent Kinase Inhibitors
- (2014) C. Sekine et al. JOURNAL OF IMMUNOLOGY
- Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial
- (2013) Josef S Smolen et al. LANCET
- Genetics of rheumatoid arthritis contributes to biology and drug discovery
- (2013) Yukinori Okada et al. NATURE
- Effect of tocilizumab combined with methotrexate on circulating biomarkers of synovium, cartilage, and bone in the LITHE study
- (2013) Anne C. Bay-Jensen et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment
- (2012) P. Emery RHEUMATOLOGY
- Comparison of joint destruction between standard- and low-dose etanercept in rheumatoid arthritis from the Prevention of Cartilage Destruction by Etanercept (PRECEPT) study
- (2012) M. Tada et al. RHEUMATOLOGY
- Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire
- (2011) B. Haraoui et al. ANNALS OF THE RHEUMATIC DISEASES
- Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)
- (2011) G K Schwartz et al. BRITISH JOURNAL OF CANCER
- Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
- (2011) K. T. Flaherty et al. CLINICAL CANCER RESEARCH
- Development of Novel Combination Therapies
- (2011) Janet Woodcock et al. NEW ENGLAND JOURNAL OF MEDICINE
- State-of-the-art: rheumatoid arthritis
- (2010) I. B. McInnes et al. ANNALS OF THE RHEUMATIC DISEASES
- PADI4 polymorphism predisposes male smokers to rheumatoid arthritis
- (2010) Y. Kochi et al. ANNALS OF THE RHEUMATIC DISEASES
- Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis
- (2010) C. Salliot et al. ANNALS OF THE RHEUMATIC DISEASES
- Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials
- (2010) L. Campbell et al. RHEUMATOLOGY
- Gene-environment interaction between the DRB1 shared epitope and smoking in the risk of anti-citrullinated protein antibody-positive rheumatoid arthritis: All alleles are important
- (2009) Emeli Lundström et al. ARTHRITIS AND RHEUMATISM
- Are new agents needed to treat RA?
- (2009) Peter E. Lipsky Nature Reviews Rheumatology
- Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells
- (2008) Clare A. Notley et al. JOURNAL OF EXPERIMENTAL MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started